Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-04-26 |
Sage Therapeutics (USA - MA) |
|
|
nomination |
CNS diseases |
Nomination |
2017-04-25 |
CTI BioPharma - previously known as Cell Therapeutics (USA - WA) - Servier (France) |
Pixuvri® (pixantrone) |
aggressive B-cell non-Hodgkin lymphoma (NHL) who failed two or three prior lines of therapy |
licensing, collaboration |
Cancer - Oncology |
Licensing agreement |
2017-04-25 |
BMS (USA - NY) Transgene (France) |
TG4010 and Opdivo® |
non-small cell lung cancer (NSCLC) |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-04-25 |
European Molecular Biology Laboratory (EMBL) (Germany) Enamine (Ukraine) |
library synthesis, medicinal chemistry and biological services |
|
collaboration |
Cancer - Oncology |
Collaboration agreement |
2017-04-25 |
AstraZeneca (UK) |
Cambridge Biomedical Campus |
|
opening of new premises |
|
Opening of new premises |
2017-04-25 |
DelMar Pharmaceuticals (USA - CA) Duke University (USA - NC) |
VAL-083 (dianhydrogalactitol) |
glioblastoma multiforme |
collaboration - R&D -research |
Cancer - Oncology |
Collaboration agreement |
2017-04-25 |
Amag Pharmaceuticals (USA - MA) |
|
|
nomination |
|
Nomination |
2017-04-25 |
Quantum Genomics (France) |
|
|
nomination |
Cardiovascular diseases |
Nomination |
2017-04-25 |
Sangamo Therapeutics (USA - CA) |
member of the board of directors |
|
resignation |
Rare diseases - Genetic diseases |
Resignation |
2017-04-24 |
Amgen (USA - CA) Novartis (Switzerland) |
AMG 334 (erenumab), AMG 301, BACE inhibitor program including CNP520 |
Alzheimer\'s disease, migraine |
development
licensing
commercialisation |
CNS diseases - Neurological diseases - Neurodegenerative diseases |
Commercialisation agreement |
2017-04-24 |
Transgene (France) Sillajen (Republic of Korea) |
JX-594/TG6006 (Pexa-Vec -pexastimogene devacirepvec) |
hepatocellular carcinoma |
development
commercialisation |
Cancer - Oncology |
Milestone |
2017-04-24 |
OncoMed Pharmaceuticals (USA - CA) |
|
|
restructuring |
Cancer - Oncology |
Restructuring |
2017-04-24 |
Paratek Pharmaceuticals (USA - MA) Zai Lab (China) |
omadacycline |
|
development - commercialisation |
Infectious diseases |
Development agreement |
2017-04-21 |
Atara Biotherapeutics (USA - CA) Merck&Co (USA - NJ) |
ATA129 and Keytruda® (pembrolizumab |
platinum resistant or recurrent EBV-associated nasopharyngeal carcinoma |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-04-20 |
Thrombogenics (Belgium) Bicycle Therapeutics (UK) |
therapeutics based on Bicycle’s bicyclic peptides |
ophtalmological diseases |
collaboration - licensing |
Ophtalmological diseases |
Milestone |
2017-04-20 |
Allergan (Ireland) TARGET PharmaSolutions |
|
NASH (non-alcoholic steatohepatitis), NAFLD (non-alcoholic fatty liver disease) |
clinical research |
Hepatic diseases - Liver diseases |
Clinical research agreement |
2017-04-19 |
Lion Biotechnologies (USA - CA) The University of Texas MD Anderson Cancer Center (USA - TX) |
TIL therapy - Tumor infiltrating lymphocytes therapy |
ovarian cancer, sarcomas, pancreatic cancer |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-04-19 |
Transgene (France) |
members of board of directors |
|
nomination |
Cancer - Oncology - Infectious diseases |
Nomination |
2017-04-18 |
Merck KGaA (Germany) Australian Institute of Tropical Health and Medicine (Australia) Baylor College of Medicine (USA - TX) |
|
schistosomiasis |
collaboration |
Parasitic diseases |
Collaboration agreement |
2017-04-18 |
Allergan (Ireland) Novartis (Switzerland) |
LJN452 (FXR agonist) and cenicriviroc (CVC) |
NASH (non-alcoholic steatohepatitis) |
clinical research |
Hepatic diseases - Liver diseases |
Clinical research agreement |